Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial-Reference-Cited by-同舟云学术

Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial

Published:2022-08 Issue:8 Volume:10 Page:785-795
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Ochoa-Azze Rolando,Chang-Monteagudo Arturo,Climent-Ruiz Yanet,Macías-Abraham Consuelo,Valenzuela-Silva Carmen,de los Ángeles García-García María,Jerez-Barceló Yanet,Triana-Marrero Yenisey,Ruiz-Villegas Laura,Dairon Rodríguez-Prieto Luis,Guerra-Chaviano Pedro Pablo,Sánchez-Ramírez Belinda,Hernández-García Tays,Orosa-Vázquez Ivette,Díaz-Hernández Marianniz,Chiodo Fabrizio,Calcagno Andrea,Ghisetti Valeria,Rodríguez-Acosta Mireida,Noa-Romero Enrique,Enríquez-Puertas Juliet,Ortega-León Darién,Valdivia-Álvarez Irinia,Delahanty-Fernández Aurora,Palenzuela-Díaz Ariel,Rodríguez-Noda Laura,González-Mugica Raúl,Valdés-Balbín Yury,García-Rivera Dagmar,Verez-Bencomo Vicente

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference37 articles.

1. WHO coronavirus (COVID-19) dashboard,2021

2. Immunological considerations for COVID-19 vaccine strategies;Jeyanathan;Nat Rev Immunol,2020

3. Substantial underestimation of SARS-CoV-2 infection in the United States;Wu;Nat Commun,2020

4. Relationship between anti-spike protein antibody titers and SARS-CoV-2 in vitro virus neutralization in convalescent plasma;Salazar;bioRxiv,2020

5. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability;Brouwer;Science,2020

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcoming colonialism in pathogen genomics;The Lancet Digital Health;2024-07

2. Role of N343 glycosylation on the SARS-CoV-2 S RBD structure and co-receptor binding across variants of concern;eLife;2024-06-12

3. Role of N343 glycosylation on the SARS-CoV-2 S RBD structure and co-receptor binding across variants of concern;eLife;2024-06-12

4. Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2–11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study;The Lancet Regional Health - Americas;2024-06

5. #GotGlycans: Role of N343 Glycosylation on the SARS-CoV-2 S RBD Structure and Co-Receptor Binding Across Variants of Concern;2024-05-23